The US Bankruptcy Court gave an order approving the sale of the certain assets of Epirus Biopharmaceuticals, Inc. on October 9, 2018. The debtor has been authorized to sell its certain assets to AnaBios Corporation for a purchase price of $0.15 million in cash pursuant to the asset purchase agreement dated August 24, 2018. The debtor’s assets include intellectual property and certain technology consisting of patents, applications, tangible property. Under the terms of the asset purchase agreement, the buyer shall make an earnest money deposit of $0.03 million upon the execution of the agreement. The buyer would be entitled to a break-up fee and expense reimbursement of $0.01 million in case of termination of the asset purchase agreement. The buyer is represented by Melissa Siegel of Wilson Sonsini Goodrich & Rosati as its legal advisors.